Immunology Department Metrics

View the clinical trials, grants and publications from the Department of Immunology.

Clinical Trials
CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 19837
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients with Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: IL-2 (Interleukin-2); MESNA (); TIL (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 19877
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
Condition: Malignant Hematology
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); Varlilumab ()

CLINICAL TRIAL 20042
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients with MDS and Secondary AML
Condition: Malignant Hematology
Intervention: Cladribine (); Cytarabine (Cytosine Arabinoside); Daunomycin (daunorubicin); G-CSF (); Idarubicin (); Zevados (Idarubicin); daunorubicin ()

CLINICAL TRIAL 20131
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); G-CSF (); Melphalan (); Mycophenolate Mofetil (); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus (); Tacrolimus (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20253
Open Label, Multi-Center, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: CT053 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20348
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III randomized study of chemoradiation versus chemoradiation plus Atezolizumab
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); Paraplatin (carboplatin); Radiotherapy (); carboplatin (); cisplatin (); etoposide ()

CLINICAL TRIAL 20313
Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (Tavo) plus Electroporation in Combination with Intravenous Nivolumab in Patients with Operable Locally- Regionally Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); Tavo-EP ()

CLINICAL TRIAL 20397
A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Condition: Immunotherapy
Intervention: Itacitinib (); Placebo ()

CLINICAL TRIAL 20487
Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab (); Radiotherapy (); Trastuzumab (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)

CLINICAL TRIAL 20578
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Condition: Malignant Hematology
Intervention: ALLO-501A (); ALLO-647 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20575
A Phase 1 Study of CG0070 Combined with Nivolumab in Cisplatin Ineligible Patients with Muscle Invasive Bladder Cancer (MIBC)
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); CG0070 (); DDM (); Nivolumab (Opdivo)

CLINICAL TRIAL 20571
Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy
Condition: Immunotherapy
Intervention: CD19 CAR T Cells (); PCV13 ()

CLINICAL TRIAL 20711
A Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Condition: Genitourinary
Intervention: CG0070 (); DDM (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20737
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
Condition: Malignant Hematology
Intervention: cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); lisocabtagene maraleucel ()

CLINICAL TRIAL 20720
S1827, MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Condition: Thoracic
Intervention:

CLINICAL TRIAL 20877
A Phase Ib /Randomized Phase III Trial of Patients with Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation with Either Orca-T, a T-cell-Depleted Graft with Additional Infusion of Conventional T cells and Regulatory T cells, or Standard-of-Care Allogeneic Graft
Condition: Malignant Hematology
Intervention: FK506 (Tacrolimus); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus (); Tacrolimus ()

CLINICAL TRIAL 20778
Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym M (ALVR-105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant
Condition: Malignant Hematology
Intervention: Viralym-M/Placebo ()

CLINICAL TRIAL 20794
Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 20923
A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Condition: Malignant Hematology
Intervention: Fedratinib ()

CLINICAL TRIAL 21023
Open Label, Multicenter Phase II Study of the C5A- Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients with PD-1- or PD-L1-Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
Condition: Cutaneous
Intervention: IFX-1 (); Not Applicable (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20903
A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy (DUART)
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); Durvalumab (); MEDI4736 (Durvalumab)

CLINICAL TRIAL 21239
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Sargramostim (); Yervoy (Ipilimumab)

CLINICAL TRIAL 21344
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Melanoma (Morpheus-Melanoma)
Condition: Cutaneous
Intervention: Atezolizumab (Tecentriq); BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); RO7247669 (); Tiragolumab (); Yervoy (Ipilimumab)

CLINICAL TRIAL 21375
A Multicenter Validation of Genomic Subtyping and Whole Transcriptome Profiling for Predicting Non-Organ Confined Disease in Patients with Clinical T1/T2 Urothelial Carcinoma of the Bladder
Condition: Genitourinary
Intervention:

CLINICAL TRIAL 21448
Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer
Condition: Breast
Intervention:

Grants
  • 2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
    Sponsor: Nat Institutes of Health
    PI (Contact):Wright, K.,PI (MPI):Monteiro, A.
  • Production Assistance for Cellular Therapies (PACT) - Cell Processing Facilities
    Sponsor: Nat Institutes of Health
    PI:Kelley, L.
  • Augmenting T Cell Trafficking and Functionality through Novel Combinations of Epigenetic Agents and PD-1 Blockade
    Sponsor: Nat Institutes of Health
    PI:Beg, A.
  • Regulatory Dendritic Cells in Cancer
    Sponsor: Nat Institutes of Health
    PI:Conejo-Garcia, J.
  • Defining Impact of HDAC Inhibitors on Tumor Immunogenicity, T Cell Functionality and PD-1 Blockade Response in NSCLC Patients
    Sponsor: US Army
    PI:Beg, A.
  • Regulation of dendritic cell function and tumor immunity by TIM-3
    Sponsor: Nat Institutes of Health
    PI:Ruffell, B.
  • B Cell-dependent Anti-tumor Immunity in Ovarian Cancer
    Sponsor: Nat Institutes of Health
    PI:Conejo-Garcia, J.
  • Functional reprogramming of tumor-MDSC through antibody-based therapies Targeting Notch Ligands
    Sponsor: Nat Institutes of Health
    PI:Rodriguez, P.
  • Imaging Acidosis and Immune Therapy in PDAC
    Sponsor: Nat Institutes of Health
    PI (Contact):Pilon-Thomas, S.,PI:Gillies, R.
  • Targetable Epidgenetic Mechanism Driving Cutaneous T Cell Lymphoma
    Sponsor: Nat Institutes of Health
    PI (Contact):Conejo-Garcia, J.,PI (MPI):Pinilla, J.,PI (MPI):Sokol, L.
  • Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment.
    Sponsor: Nat Institutes of Health
    PI:Abate Daga, D.
  • Breast cancer immunotherapy with anti-TIM-3
    Sponsor: US Army
    PI:Ruffell, B.
  • Exploiting the Immune Mapping of the Tumor Microenvironment to Improve Immunotherapy of Melanoma
    Sponsor: Adelson (Miriam & Sheldon) Medical Res Fdtn
    PI:Mulé, J.
  • Determine the effects of the TP-0184 and its derivatives (second generation) on myeloid-derived suppressor cell (MDSC)-mediated suppressive functions and improve the local bone marrow (BM) microenvironment in patients with MDS
    Sponsor: Sumitomo Dainippon Pharma Oncology
    PI (Contact):Wright, K.,PI:Eksioglu, E.
  • Intellia Research Collaboration - Project 1: Advancing Neoantigen-Specific T Cells
    Sponsor: Intellia Therapeutics
    PI:Pilon-Thomas, S.,CO-PI:Abate Daga, D.
  • A Phase II Biomarker Trial of CC-122 in Combination with Nivolumab in Advanced Melanoma
    Sponsor: Celgene Corp.
    PI:Pilon-Thomas, S.
  • Notch signaling boosts T cell-based immunotherapy
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Rodriguez, P.,CO-PI:Luca, V.
  • Myst/Turnstone– Moffitt Collaboration - Melanoma & Colorectal
    Sponsor: Turnstone Biologics
    PI (Contact):Pilon-Thomas, S.,CO-PI:Beatty, M.,CO-PI:Fleming, J.,CO-PI:Teer, J.,CO-PI:Mulé, J.
  • THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCE
    Sponsor: Nat Institutes of Health
    PI:Conejo-Garcia, J.
  • Dissecting the immunological mechanisms associated with prostate cancer progression in African-American men and exploring epigenetics-based immune modulation for therapy
    Sponsor: Nat Institutes of Health
    PI:Adeegbe, D.
  • NSG Mouse Models to Evaluate the Efficacy of TIL
    Sponsor: Iovance Biotherapeutics
    PI:Pilon-Thomas, S.
  • Tumor infiltrating B-cells and Melanoma TIL
    Sponsor: Moffitt Cancer Center
    PI:Abate Daga, D.,CO-PI:Pilon-Thomas, S.
  • Role of Bcl11b in CD4+ T Cells and Innate Lymphoid Cells
    Sponsor: Nat Institutes of Health
    PI:Avram, D.
  • High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase
    Sponsor: Nat Institutes of Health
    PI (MPI):Avram, D.
  • Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury
    Sponsor: Nat Institutes of Health
    PI:Avram, D.
  • Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds
    Sponsor: Nat Institutes of Health
    PI:Rodriguez, P.
  • Validating and tailored targeting of identified immune signature in the tumors of African-American Prostate cancer patients
    Sponsor: Mike Slive Foundation
    PI:Adeegbe, D.
  • Actionable cell stress mechanisms governing αb and gd T cell responses against ovarian cancer
    Sponsor: Moffitt Cancer Center
    PI (Contact):Conejo-Garcia, J.,CO-PI:Rodriguez, P.,CO-PI:Tworoger, S.
  • Metabolic cooperation between macrophages and prostate cancer cells as a mechanism of resistance
    Sponsor: Moffitt Cancer Center
    PI:Ruffell, B.
  • Mechanisms of functional heterogeneity of tumor associated macrophages in glioblastoma
    Sponsor: Ivy (Ben & Catherine) Fdtn
    PI:Veglia, F.
  • Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells
    Sponsor: Nat Institutes of Health
    PI:Guevara, J.
  • Tech Transfer support and clinical protocol development for the use of TIL in patients with melanoma
    Sponsor: Turnstone Biologics
    PI:Pilon-Thomas, S.,CO-PI:Mulé, J.
  • Heterogeneity of metastatic small cell lung cancer; implications for the design of effective immunotherapies
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI (Contact):Conejo-Garcia, J.,CO-PI:Perez, B.
  • Targeting ENPP1 to promote immunity during PARP inhibition in TNBC
    Sponsor: US Army
    PI (Contact):Ruffell, B.
  • Transdermal Alkalinization Treatment as an Adjunct in Melanoma Therapy
    Sponsor: Dyve Biosciences
    PI:Pilon-Thomas, S.,CO-PI:Gillies, R.
  • Evaluating TIM-3 combination therapies in castration-resistant prostate cancer
    Sponsor: Mike Slive Foundation
    PI:Ruffell, B.
  • Evaluating ENPP1 as a therapeutic target in TNBC
    Sponsor: Moffitt Cancer Center
    PI (Contact):Ruffell, B.,CO-PI:Luca, V.
Publications
  • Anadon CM, Yu X, Hänggi K, Biswas S, Chaurio RA, Martin A, Payne KK, Mandal G, Innamarato P, Harro CM, Mine JA, Sprenger KB, Cortina C, Powers JJ, Costich TL, Perez BA, Gatenbee CD, Prabhakaran S, Marchion D, Heemskerk MHM, Curiel TJ, Anderson AR, Wenham RM, Rodriguez PC, Conejo-Garcia JR. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022 May.40(5):545-557.e13. Pubmedid: 35427494.
  • Peres LC, Colin-Leitzinger C, Sinha S, Marks JR, Conejo-Garcia JR, Alberg AJ, Bandera EV, Berchuck A, Bondy ML, Christensen BC, Cote ML, Doherty JA, Moorman PG, Peters ES, Moran Segura C, Nguyen JV, Schwartz AG, Terry PD, Wilson CM, Fridley BL, Schildkraut JM. Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma. Cancer Epidemiol Biomarkers Prev. 2022 May.31(5):1006-1016. Pubmedid: 35244678. Pmcid: PMC9081269.
  • Song X, Chang S, Seminario-Vidal L, de Mingo Pulido A, Tordesillas L, Song X, Reed RA, Harkins A, Whiddon S, Nguyen JV, Moran Segura C, Zhang C, Yoder S, Sayegh Z, Zhao Y, Messina JL, Harro CM, Zhang X, Conejo-Garcia JR, Berglund AE, Sokol L, Zhang J, Rodriguez PC, Mule JJ, Futreal AP, Tsai KY, Chen PL. Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma. Cancer Discov. 2022 May.12(5):1294-1313. Pubmedid: 35247891.
  • Yu X, Cen L, Chen YA, Markowitz J, Shaw TI, Tsai KY, Conejo-Garcia JR, Wang X. Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures. Cancer Res. 2022 May.82(9):1724-1735. Pubmedid: 35176128. Pmcid: PMC9064917.
  • Creasy CA, Meng YJ, Forget MA, Karpinets T, Tomczak K, Stewart C, Torres-Cabala CA, Pilon-Thomas S, Sarnaik AA, Mule JJ, Garraway L, Bustos M, Zhang J, Patel SP, Diab A, Glitza IC, Yee C, Tawbi H, Wong MK, McQuade J, Hoon DSB, Davies MA, Hwu P, Amaria RN, Haymaker C, Beroukhim R, Bernatchez C. Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res. 2022 May.28(9):1911-1924. Pubmedid: 35190823. Pmcid: PMC9064946.
  • Oshrine B, Innamarato P, Branthoover H, Nagle L, Verdugo P, Pilon-Thomas S, Beatty M. Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2022 Apr.28(4):203.e1-203.e7. Pubmedid: 34995816.
  • Newsome RC, Gharaibeh RZ, Pierce CM, da Silva WV, Paul S, Hogue SR, Yu Q, Antonia S, Conejo-Garcia JR, Robinson LA, Jobin C. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Med. 2022 Mar.14(1):35. Pubmedid: 35346337. Pmcid: PMC8961902.
  • Daniel Grass G, Alfonso JCL, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Enderling H, Torres-Roca JF. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 Mar. Pubmedid: 35289298.
  • Giuliano AR, Lancet JE, Pilon-Thomas S, Dong N, Jain AG, Tan E, Ball S, Tworoger SS, Siegel EM, Whiting J, Mo Q, Cubitt CL, Dukes CW, Hensel JA, Keenan RJ, Hwu P. Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida. JAMA Oncol. 2022 Mar. Pubmedid: 35266953. Pmcid: PMC8914884.
  • Sanchez-Pino MD, Richardson WS, Zabaleta J, Puttalingaiah RT, Chapple AG, Liu J, Kim Y, Ponder M, DeArmitt R, Baiamonte LB, Wyczechowska D, Zheng L, Al-Khami AA, Garai J, Martini R, Davis M, Gorham JK, Wooldridge JB, Rodriguez PC, Miele L, Ochoa AC. Increased inflammatory low-density neutrophils in severe obesity and effect of bariatric surgery: Results from case-control and prospective cohort studies. EBioMedicine. 2022 Mar.77:103910. Pubmedid: 35248994. Pmcid: PMC8897585.
  • Chiappori AA, Creelan B, Tanvetyanon T, Gray JE, Haura EB, Thapa R, Barlow ML, Chen Z, Chen DT, Beg AA, Boyle TA, Castro J, Morgan L, Morris E, Aregay M, Hurtado FK, Manenti L, Antonia S. Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2022 Mar. Pubmedid: 35254415.
  • Kornepati AVR, Boyd JT, Murray CE, Saifetyarova J, de la Peña Avalos B, Rogers CM, Bai H, Padron AS, Liao Y, Ontiveros C, Svatek RS, Hromas R, Li R, Hu Y, Conejo-Garcia JR, Vadlamudi RK, Zhao W, Dray E, Sung P, Curiel TJ. Tumor-intrinsic PD-L1 promotes DNA repair in distinct cancers and suppresses PARP inhibitor-induced synthetic lethality. Cancer Res. 2022 Mar. Pubmedid: 35247877.
  • Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy. Clin Cancer Res. 2022 Mar. Pubmedid: 35247927.
  • Giuliano AR, Pilon-Thomas S, Schell MJ, Abrahamsen M, Islam JY, Isaacs-Soriano K, Kennedy K, Dukes CW, Whiting J, Rathwell J, Hensel JA, Mangual LN, Schonbrunn E, Bikowitz M, Grassie D, Yang Y. SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020-March 2021. Emerg Infect Dis. 2022 Mar.28(3):556-563. Pubmedid: 35081021. Pmcid: PMC8888241.
  • Ferrall-Fairbanks MC, Chakiryan N, Chobrutskiy BI, Kim Y, Teer JK, Berglund A, Mulé JJ, Fournier M, Siegel EM, Dhillon J, Falasiri SSA, Arturo JF, Katende EN, Blanck G, Manley BJ, Altrock PM. Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. Cancer Res. 2022 Mar.82(5):929-942. Pubmedid: 35031572. Pmcid: PMC8898280.
  • Mandal G, Biswas S, Anadon CM, Yu X, Gatenbee CD, Prabhakaran S, Payne KK, Chaurio RA, Martin A, Innamarato P, Moran C, Powers JJ, Harro CM, Mine JA, Sprenger KB, Rigolizzo KE, Wang X, Curiel TJ, Rodriguez PC, Anderson ARA, Saglam O, Conejo-Garcia JR. IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. Cancer Res. 2022 Mar.82(5):859-871. Pubmedid: 34949671. Pmcid: PMC8898267.
  • Obermayer A, Dong L, Hu Q, Golden M, Noble JD, Rodriguez P, Robinson TJ, Teng M, Tan AC, Shaw TI. DRPPM-EASY: A Web-Based Framework for Integrative Analysis of Multi-Omics Cancer Datasets. Biology (Basel). 2022 Feb.11(2). Pubmedid: 35205126. Pmcid: PMC8869715.
  • Law V, Chen Z, Vena F, Smalley I, Macaulay R, Evernden BR, Tran N, Pina Y, Puskas J, Caceres G, Bayle S, Johnson J, Liu JKC, Etame A, Vogelbaum M, Rodriguez P, Duckett D, Czerniecki B, Chen A, Smalley KSM, Forsyth PA. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neurooncol. 2022 Feb. Pubmedid: 35213727.
  • Bag A, Schultz A, Bhimani S, Stringfield O, Dominguez W, Mo Q, Cen L, Adeegbe D. Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer. Oncoimmunology. 2022 Feb.11(1):2042065. Pubmedid: 35223194. Pmcid: PMC8865306.
  • Saglam O, Cao B, Wang X, Toruner GA, Conejo-Garcia JR. Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma. PLoS One. 2022 Feb.17(2):e0264014. Pubmedid: 35226658. Pmcid: PMC8884513.
  • Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA, Guenot J, Markowitz J, Cleveland JL, Wright KL, List AF, Wei S, Eksioglu EA. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma. Mol Ther. 2022 Feb. Pubmedid: 35150889.
  • Donthireddy L, Vonteddu P, Murthy T, Kwak T, Eraslan RN, Podojil JR, Elhofy A, Boyne MT, Puisis JJ, Veglia F, Singh SS, Dotiwala F, Montaner LJ, Gabrilovich DI. ONP-302 Nanoparticles Inhibit Tumor Growth By Altering Tumor-Associated Macrophages And Cancer-Associated Fibroblasts. J Cancer. 2022 Mar.13(6):1933-1944. Pubmedid: 35399717. Pmcid: PMC8990435.
  • Tarhini AA, Lee SJ, Tan AC, El Naqa IM, Stephen Hodi F, Butterfield LH, LaFramboise WA, Storkus WJ, Karunamurthy AD, Conejo-Garcia JR, Hwu P, Streicher H, Sondak VK, Kirkwood JM. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022 Jan.10(1). Pubmedid: 35074904. Pmcid: PMC8788316.
  • Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, Moran C, Ortiz AC, Cortina C, Rigolizzo KE, Sprenger KB, Mine JA, Innamarato P, Mandal G, Powers JJ, Martin A, Wang Z, Mehta S, Perez BA, Li R, Robinson J, Kroeger JL, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR. TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity. 2022 Jan.55(1):115-128.e9. Pubmedid: 35021053. Pmcid: PMC8852221.
  • Gardner A, de Mingo Pulido Á, Hänggi K, Bazargan S, Onimus A, Kasprzak A, Conejo-Garcia JR, Rejniak KA, Ruffell B. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+ T cell and XCR1+ dendritic cell spatial co-localization. J Immunother Cancer. 2022 Jan.10(1). Pubmedid: 34987021. Pmcid: PMC8734033.
  • Basu A, Albert GK, Awshah S, Datta J, Kodumudi KN, Gallen C, Beyer A, Smalley KSM, Rodriguez PC, Dukett DR, Forsyth PA, Soyano A, Koski GK, Lima Barros Costa R, Han H, Soliman H, Lee MC, Kalinski P, Czerniecki BJ. Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine. Cancer Immunol Res. 2022 Jan.10(1):108-125. Pubmedid: 34785506.
  • Zhang Y, Seminario-Vidal L, Varnadoe C, Lu Y, Dong N, Salamanca C, Whiddon S, Bennett J, Hargis R, Liu H, Montejo M, Hussaini M, Harro C, Messina J, Benson K, Pinilla-Ibarz J, Conejo-Garcia J, Sokol L. Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center. Leuk Lymphoma. 2022 Jan.63(1):109-116. Pubmedid: 34467825.
  • Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, Sudalagunta P, Canevarolo RR, Siqueira Silva MDC, Alugubelli RR, Dai HA, Kulkarni A, Dalton WS, Hampton OA, Welsh EA, Teer JK, Tungesvik A, Wright KL, Pinilla-Ibarz J, Sotomayor EM, Shain KH, Brayer J. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021 Dec.6(24). Pubmedid: 34793338. Pmcid: PMC8783683.
  • Rollison DE, Messina JL, Cherpelis BS, Fenske NA, Schell MJ, Adeegbe DO, Zhao Y, Amorrortu RP, Akuffo AA, Hesterberg RS, Epling-Burnette PK. Circulating Immunosuppressive Regulatory T Cells Predict Risk of Incident Cutaneous Squamous Cell Carcinoma. Front Med (Lausanne). 2021 Nov.8:735585. Pubmedid: 34796183. Pmcid: PMC8593034.
  • Alfonso JCL, Grass GD, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Torres-Roca JF, Enderling H. Tumor-immune ecosystem dynamics define an individual Radiation Immune Score to predict pan-cancer radiocurability. Neoplasia. 2021 Nov.23(11):1110-1122. Pubmedid: 34619428. Pmcid: PMC8502777.
  • Mandriani B, Pelle' E, Pezzicoli G, Strosberg J, Abate-Daga D, Guarini A, Cives M, Porta C. Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. Cancer Treat Rev. 2021 Nov.100:102288. Pubmedid: 34525422.
  • El-Kenawi A, Dominguez-Viqueira W, Liu M, Awasthi S, Abraham-Miranda J, Keske A, Steiner KK, Noel L, Serna AN, Dhillon J, Gillies RJ, Yu X, Koomen JM, Yamoah K, Gatenby RA, Ruffell B. Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer. Cancer Res. 2021 Nov.81(21):5477-5490. Pubmedid: 34301759. Pmcid: PMC8563406.
  • Sharma MD, Pacholczyk R, Shi H, Berrong ZJ, Zakharia Y, Greco A, Chang CS, Eathiraj S, Kennedy E, Cash T, Bollag RJ, Kolhe R, Sadek R, McGaha TL, Rodriguez P, Mandula J, Blazar BR, Johnson TS, Munn DH. Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. Immunity. 2021 Oct.54(10):2354-2371.e8. Pubmedid: 34614413. Pmcid: PMC8516719.
  • Kim MC, Borcherding N, Ahmed KK, Voigt AP, Vishwakarma A, Kolb R, Kluz PN, Pandey G, De U, Drashansky T, Helm EY, Zhang X, Gibson-Corley KN, Klesney-Tait J, Zhu Y, Lu J, Lu J, Huang X, Xiang H, Cheng J, Wang D, Wang Z, Tang J, Hu J, Wang Z, Liu H, Li M, Zhuang H, Avram D, Zhou D, Bacher R, Zheng SG, Wu X, Zakharia Y, Zhang W. CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. Nat Commun. 2021 Oct.12(1):5764. Pubmedid: 34599187. Pmcid: PMC8486774.
  • Engelhard V, Conejo-Garcia JR, Ahmed R, Nelson BH, Willard-Gallo K, Bruno TC, Fridman WH. B cells and cancer. Cancer Cell. 2021 Oct.39(10):1293-1296. Pubmedid: 34597591.
  • Jaishankar D, Cosgrove C, Ramesh P, Mahon J, Shivde R, Dellacecca ER, Yang SF, Mosenson J, Guevara-Patiño JA, Le Poole IC. HSP70iQ435A to subdue autoimmunity and support anti-tumor responses. Cell Stress Chaperones. 2021 Sep.26(5):845-857. Pubmedid: 34542825. Pmcid: PMC8492854.
  • de la Iglesia JV, Slebos RJC, Martin-Gomez L, Wang X, Teer JK, Tan AC, Gerke TA, Aden-Buie G, van Veen T, Masannat J, Chaudhary R, Song F, Fournier M, Siegel EM, Schabath MB, Wadsworth JT, Caudell J, Harrison L, Wenig BM, Conejo-Garcia J, Hernandez-Prera JC, Chung CH. Correction: Effects of Tobacco Smoking On the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2021 Sep.27(17):4941. Pubmedid: 34470812.
  • Li R, Zhang J, Gilbert SM, Conejo-Garcia J, Mulé JJ. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nat Rev Urol. 2021 Sep.18(9):543-555. Pubmedid: 34183833.
  • Koşaloğlu-Yalçın Z, Blazeska N, Carter H, Nielsen M, Cohen E, Kufe D, Conejo-Garcia J, Robbins P, Schoenberger SP, Peters B, Sette A. The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. Front Immunol. 2021 Aug.12:735609. Pubmedid: 34504503. Pmcid: PMC8421848.
  • Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug.27(8):1410-1418. Pubmedid: 34385708. Pmcid: PMC8509078.
  • Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021 Aug.21(8):485-498. Pubmedid: 33526920. Pmcid: PMC7849958.
  • Chakiryan NH, Kimmel GJ, Kim Y, Johnson JO, Clark N, Hajiran A, Chang A, Aydin AM, Zemp L, Katende E, Chahoud J, Ferrall-Fairbanks MC, Spiess PE, Francis N, Fournier M, Dhillon J, Park JY, Wang L, Mulé JJ, Altrock PM, Manley BJ. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021 Jul.13(15). Pubmedid: 34359645. Pmcid: PMC8345222.
  • Kirtane K, Elmariah H, Chung CH, Abate-Daga D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunother Cancer. 2021 Jul.9(7). Pubmedid: 34301811. Pmcid: PMC8311333.
  • Rodriguez PC, Ruffell B. Cavity macrophages stop anti-tumor T cells. Cancer Cell. 2021 Jul.39(7):900-902. Pubmedid: 34256904.
  • Chen DT, Chan W, Thompson ZJ, Thapa R, Beg AA, Saltos AN, Chiappori AA, Gray JE, Haura EB, Rose TA, Creelan B. Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS One. 2021 Jul.16(7):e0252041. Pubmedid: 34197475. Pmcid: PMC8248740.
  • Smalley I, Chen Z, Phadke MS, Li J, Yu X, Wyatt C, Evernden B, Messina JL, Sarnaik A, Sondak VK, Zhang C, Law V, Tran N, Etame A, Macaulay RJB, Eroglu Z, Forsyth PA, Rodriguez PC, Chen YA, Smalley KSM. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clin Cancer Res. 2021 Jul.27(14):4109-4125. Pubmedid: 34035069. Pmcid: PMC8282775.
  • Li R, Berglund A, Zemp L, Dhillon J, Putney R, Kim Y, Jain RK, Grass GD, Conejo-Garcia J, Mulé JJ. The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. Front Immunol. 2021 Jun.12:694079. Pubmedid: 34267760. Pmcid: PMC8276102.
  • Innamarato P, Morse J, Mackay A, Asby S, Beatty M, Blauvelt J, Kidd S, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors. BMC Cancer. 2021 Jun.21(1):756. Pubmedid: 34187428. Pmcid: PMC8243723.
  • Aoyama S, Nakagawa R, Nemoto S, Perez-Villarroel P, Mulé JJ, Mailloux AW. Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment. J Immunother Cancer. 2021 Jun.9(6). Pubmedid: 34135102. Pmcid: PMC8211075.
  • Li MO, Wolf N, Raulet DH, Akkari L, Pittet MJ, Rodriguez PC, Kaplan RN, Munitz A, Zhang Z, Cheng S, Bhardwaj N. Innate immune cells in the tumor microenvironment. Cancer Cell. 2021 Jun.39(6):725-729. Pubmedid: 34129817.
  • Van Vliet A, Girardot A, Bouchez J, Bigness A, Wang K, Moino D, Theodotou A, Pothuraju T, Felder S, Smith P, Kumar A, Dayicioglu D. How Big Is Too Big?: The Effect of Defect Size on Postoperative Complications of Vertical Rectus Abdominis Flap Reconstruction. Ann Plast Surg. 2021 Jun.86(6S Suppl 5):S571-S574. Pubmedid: 34100815.
  • de Mingo Pulido Á, Hänggi K, Celias DP, Gardner A, Li J, Batista-Bittencourt B, Mohamed E, Trillo-Tinoco J, Osunmakinde O, Peña R, Onimus A, Kaisho T, Kaufmann J, McEachern K, Soliman H, Luca VC, Rodriguez PC, Yu X, Ruffell B. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity. 2021 Jun.54(6):1154-1167.e7. Pubmedid: 33979578. Pmcid: PMC8192496.